ICU Medical Inc
NASDAQ:ICUI
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
108.1
172.3
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
ICU Medical Inc
ICU Medical Inc. emerged as an intriguing player in the healthcare sector, focusing on a mission-critical niche within the industry—safety and efficiency in medical devices for infusion therapy, oncology, and critical care applications. Founded with an innovative spirit, the company carved out a reputation by addressing a key challenge in the medical field: preventing bloodstream infections and the exposure of healthcare professionals to hazardous substances. This focus led to the development of specialized devices such as needle-free connectors and closed system transfer devices, which are integral to minimizing contamination risks. These innovations not only improved patient outcomes but also enhanced the working conditions of medical professionals, underpinning ICU Medical’s growth trajectory.
ICU Medical generates revenue by designing and manufacturing these life-saving devices, which are distributed across hospitals and healthcare facilities worldwide. The company's business model revolves around creating products that align with strict regulatory standards, ensuring both safety and superiority in healthcare settings. As they ventured into diverse product lines, such as infusion pumps and systems, the firm leveraged strategic acquisitions to expand market reach and technological capabilities. These initiatives underscored ICU Medical's commitment to operational synergy and product innovation, enabling the company to remain competitive and continue scaling its operations in a constantly evolving healthcare landscape. With a steady focus on both organic growth and strategic partnerships, ICU Medical remains a crucial player in the global health economy, dedicated to advancing patient care and the efficiency of healthcare delivery systems.
ICU Medical Inc. emerged as an intriguing player in the healthcare sector, focusing on a mission-critical niche within the industry—safety and efficiency in medical devices for infusion therapy, oncology, and critical care applications. Founded with an innovative spirit, the company carved out a reputation by addressing a key challenge in the medical field: preventing bloodstream infections and the exposure of healthcare professionals to hazardous substances. This focus led to the development of specialized devices such as needle-free connectors and closed system transfer devices, which are integral to minimizing contamination risks. These innovations not only improved patient outcomes but also enhanced the working conditions of medical professionals, underpinning ICU Medical’s growth trajectory.
ICU Medical generates revenue by designing and manufacturing these life-saving devices, which are distributed across hospitals and healthcare facilities worldwide. The company's business model revolves around creating products that align with strict regulatory standards, ensuring both safety and superiority in healthcare settings. As they ventured into diverse product lines, such as infusion pumps and systems, the firm leveraged strategic acquisitions to expand market reach and technological capabilities. These initiatives underscored ICU Medical's commitment to operational synergy and product innovation, enabling the company to remain competitive and continue scaling its operations in a constantly evolving healthcare landscape. With a steady focus on both organic growth and strategic partnerships, ICU Medical remains a crucial player in the global health economy, dedicated to advancing patient care and the efficiency of healthcare delivery systems.
Revenue Growth: ICU Medical reported Q3 revenue of $533 million, with 5% organic growth but minus 8% reported year-over-year, impacted by the deconsolidation of IV Solutions.
Profitability: Gross margin rose to 41%, with adjusted EBITDA up 12% to $106 million and adjusted EPS up 28% to $2.03, helped by higher margins and lower operating expenses.
Guidance Raised: Full-year EBITDA guidance was increased to $395–$405 million (from $380–$390 million), and adjusted EPS outlook raised to $7.35–$7.65 (from $6.85–$7.15).
Segment Performance: Consumables and IV Systems delivered strong growth, with Consumables up 8% reported and IV Systems up 9% reported.
Cost Pressures: Tariffs remain a significant headwind, with Q3 tariff expense at $9 million and full-year tariff costs expected to reach $25 million.
Balance Sheet: Free cash flow improved, $273 million of debt repaid year-to-date, and recent refinancing expected to save $2 million annually in interest.
Innovation & Pipeline: Progress continues on product innovation and FDA approvals for new infusion hardware and software, supporting medium-term growth.
Portfolio Optimization: Management remains open to further portfolio adjustments, focusing on maximizing value and growth in core segments.